211 related articles for article (PubMed ID: 9625268)
1. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
6. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
7. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
8. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
[TBL] [Abstract][Full Text] [Related]
9. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
10. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
11. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
12. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
14. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
15. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Besancon M; Simon A; Sachs G; Shin JM
J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
[TBL] [Abstract][Full Text] [Related]
16. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
17. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
18. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
19. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]